Pacira BioSciences, Inc. (PCRX)

NMS – Real Time Price. Currency in USD

24.09

-0.29 (-1.19%)

Market open: Aug 12, 2026, 1:33 PM EDT

24.38

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 5:19 PM EDT

08.08.2026

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences is evolving from a single-product specialty pharma into a self-funded musculoskeletal pain platform with expanding pipeline optionality. EXPAREL's separate reimbursement, particularly via the NOPAIN Act and UnitedHealthcare, shifts economics and broadens institutional access, supporting recurring protocol-based utilization. The iovera° divestiture strengthens PCRX's balance sheet, funds higher-value pharmaceutical programs, and preserves upside through milestone payments.

07.08.2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on August 4, 2026 to five new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

06.08.2026

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —

05.08.2026

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.

05.08.2026

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences NASDAQ: PCRX reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet.

05.08.2026

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

04.08.2026

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Pacira (PCRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.74 per share a year ago.

Videos

No Data

There is no data to display

Press releases

07.08.2026

Pacira BioSciences, Inc. (PCRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Videos

No Data

Press releases

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Videos

No Data

Press releases

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira BioSciences Reports Second Quarter 2026 Financial Results

Search stocks

Pacira BioSciences, Inc. (PCRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Videos

No Data

Press releases

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Videos

No Data

Press releases

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira BioSciences Reports Second Quarter 2026 Financial Results